24 September 2015
EMA/PDCO/547310/2015 Corr.
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Minutes for the meeting on 12-14 August 2015

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

12 August 2015, 08:30- 19:00, room 3A

13 August 2015, 08:30- 19:00, room 3A

14 August 2015, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO meeting reports once the procedures are finalised and start of referrals will also be available.

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes were adopted with amendments and will be published on the EMA website.

2. Opinions[1]

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

[1] Please refer to the August PDCO monthly report published on the EMA Website, see PDCO meeting reports

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.4. Opinions on Re-examinations

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure October 2015 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the list of Rapporteurs.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

None.

4.3. Nominations for other activities

None.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. Discussions on first reports of SAWP products with paediatric interest

None.

5.2. Discussions on SAWP products following a discussion meeting with companies

None.

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. MSB0010718C - EMEA-29-2015

Merck KGaA; Treatment of lung carcinoma (small cell and non-small cell carcinoma)/ Treatment of advanced non-small cell lung cancer

Rapporteur: Riccardo Riccardi

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: paediatric solid tumours.

6.1.2. RVX000222 - EMEA-32-2015

Resverlogix Corp; Treatment of coronary atherosclerosis/ Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease and diabetes mellitus, in combination with high potency statins as an adjunct to correction of other risk factors and other cardioprotective therapy

Rapporteur: Angeliki Siapkara

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: fatty acid metabolism disorders, Kawasaki disease, nephrotic syndrome, obesity, and in children who are treated with anti-epilepsy medicines or who received radiation therapy.

6.1.3. JNJ-42756493 - EMEA-33-2015

Janssen-Cilag; Treatment of ureter and bladder carcinoma/Treatment of patients with metastatic or surgically unresectable urothelial carcinoma whose tumors harbor select FGFR genetic alterations

Rapporteur: Herbert Lenicker

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: paediatric tumours whose cell growth, survival and migration is sustained by fibroblast growth factors.

6.1.4. JNJ-42756493 - EMEA-34-2015

Janssen-Cilag; Treatment of lung carcinoma (small cell and non-small cell)/Treatment of metastatic or advanced lung cancer in patients who have failed on prior treatment

Rapporteur: Herbert Lenicker

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: paediatric tumours whose cell growth, survival and migration is sustained by fibroblast growth factors.

6.1.5. Ruxolitinib (Jakavi) - EMEA-35-2015

Novartis Europharm Ltd.; Treatment of adenocarcinoma of the pancreas/ Treatment of adult patients with locally advanced or metastatic adenocarcinoma of the pancreas with a modified Glasgow Prognostic Score of 1or 2, in combination with capecitabine, after failure of first-line chemotherapy

Rapporteur: Herbert Lenicker

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: acute myeloid leukaemia and acute lymphoblastic leukaemia.

6.1.6. Ruxolitinib (Jakavi) - EMEA-36-2015

Novartis Europharm Ltd.; Treatment of adenocarcinoma of the colon and rectum/ In combination with regorafenib for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies (fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy)

Rapporteur: Hendrik van den Berg

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: acute myeloid

leukaemia and acute lymphoblastic leukaemia.

6.1.7. Padeliporfin di-potassium - EMEA-37-2015

STEBA Biotech S.A.; Treatment of prostate carcinoma (excluding rhabdomyosarcoma)/ Treatment of localised prostate cancer

Rapporteur: Birka Lehmann

Summary of committee discussion:

The applicability of the class waiver to the planned therapeutic indication was confirmed. Potential paediatric interest of this medicine suggested by PDCO: none identified.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None.

8. Annual reports on deferrals

8.1.1. Telavancin – Vibativ - EMEA-000239-PIP01-08

Clinigen Healthcare Ltd

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.2. Catridecacog – NovoThirteen - EMEA-000185-PIP01-08 - Orphan

Novo Nordisk A/S

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted that there are no difficulties for progressing with the PIP as agreed.

8.1.3. N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluoro...– Tafinlar - EMEA-001147-PIP01-11

GlaxoSmithKline Trading Service Limited

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.4. Teriflunomide – Aubagio - EMEA-001094-PIP01-10

Sanofi-aventis recherche & développement

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.5. Tolvaptan – Samsca - EMEA-001231-PIP02-13

Otsuka Pharmaceutical Europe Ltd.

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.6. Teduglutide ([gly2] recombinant human glucagon-like peptide) – Revestive – EMEA-000482-PIP01-08 - Orphan

Nycomed Danmark ApS

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.7. Beclometasone dipropionate plus formoterol fumarate dihydrate – Foster and associated names, Kantos and associated names, Kantos Master and associated names, Inuvair and associated names - EMEA-000548-PIP01-09

Chiesi Farmaceutici S.p.A.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.8. Mixture of iron(III)-oxyhydroxide, sucrose, starch – Velphoro - EMEA-001061-PIP01-10

Vifor Fresenius Medical Care Renal Pharma France

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.9. Lamivudine (3TC) / Abacavir (ABC) / Dolutegravir (DTG) – Trelavue - EMEA-001219-PIP01-11

ViiV Healthcare UK Limited.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.10. Velaglucerase alfa – VPRIV - EMEA-000556-PIP01-09

Shire Pharmaceuticals Ireland Limited

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.11. 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid – Translarna - EMEA-000115-PIP01-07 - Orphan

PTC Therapeutics, Inc.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted no difficulties regarding the PIP progress as it has been agreed.

8.1.12. Poly(oxy-1,2-ethanediyl),alpha-hydro-omega-methoxy-133 ester with granulocyte co… – Lonquex - EMEA-001019-PIP01-10

Teva Pharma B.V.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.13. Regorafenib – Stivarga - EMEA-001178-PIP01-11

Bayer Pharma AG

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report

8.1.14. Aliskiren – Rasilez - EMEA-000362-PIP01-08

Novartis Europharm Ltd.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.15. Plerixafor – Mozobil - EMEA-000174-PIP01-07 – Orphan

Genzyme Europe B.V.

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report

8.1.16. Everolimus – Votubia[2] - EMEA-000019-PIP02-07 - Orphan

Novartis Europharm Limited

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

8.1.17. Everolimus – Votubia - EMEA-000019-PIP08-12 - Orphan

Novartis Europharm Limited

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.18. Perampanel – Fycompa - EMEA-000467-PIP01-08

Eisai Ltd

Difficulties progressing the PIP? Yes

Summary of committee discussion:

The PDCO noted the report.

8.1.19. Ipilimumab – Strentarga - EMEA-000117-PIP01-07

Bristol-Myers Squibb International Corporation

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

[2] Correction of the product invented name

8.1.20. Ipilimumab – Yervoy (subject to change during MAA procedure) - EMEA-000117-PIP02-10

Bristol-Myers Squibb International Corporation

Difficulties progressing the PIP? No

Summary of committee discussion:

The PDCO noted the report.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Paediatric inventories: Response to comments on endocrinology draft inventory

PDCO member: Birka Lehmann

Summary of committee discussion:

The endocrinology draft inventory of paediatric needs was adopted by the PDCO for publication on the EMA public website.

9.1.2. Paediatric inventories: Inventory of paediatric therapeutic needs - immunology

PDCO member: Birka Lehmann

Summary of committee discussion:

The immunology draft inventory of paediatric needs was discussed and further input requested from the members of the PDCO.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

Postponed to the PDCO September 2015 plenary meeting.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Summary of committee discussion:

Documents tabled for information.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

Documents tabled for information.

9.4. Cooperation within the EU regulatory network

9.4.1. List of paediatric rare diseases lacking satisfactory treatments

Summary of committee discussion:

The Committee discussed the draft document and concluded that a document describing detailed criteria to identify paediatric rare diseases lacking satisfactory treatments might be more appropriate. Therefore the current document including a specific list of rare paediatric list was not adopted.

9.5. Cooperation with International Regulators

None.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None.

9.7. PDCO work plan

None.

9.8. Planning and reporting

None.

9.9. PDCO ORGAM

None.

10. Any other business

10.1. Presentation of the Innovative Medicines Initiative 2 (IMI)project 'ADAPT-SMART'

Summary of committee discussion:

The PDCO noted the Information on the status of the IMI2 project ADAPT-SMART (**A**ccelerated **D**evelopment of **A**ppropriate **P**atient **T**herapies: a **S**ustainable, **M**ulti-stakeholder **A**pproach from **R**esearch to **T**reatment-outcomes). The ADAPT-SMART consortium will facilitate and accelerate the availability of Medicines Adaptive Pathways to Patients (MAPPs). MAPPs seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion. The partners are public authorities and private companies. The project started in July 2015 and the duration is 30 months.

PDCO member were invited to express their interest to contribute to the project by end of August 2015.

10.2. Consultation of Scientific committees on 'Draft guidance on uncertainty in scientific assessments' developed by the European Food Safety Authority (EFSA) until 4 September

Summary of committee discussion:

PDCO members nominated to review the EFSA document did not identified any direct impact on the PDCO work. The Committee concluded that there were no comments to be sent on the guidance.

10.3. Elaboration of PDCO position with regard to fixed drug combinations of antihypertensives in the paediatric population

PDCO member: Helena Fonseca

Summary of committee discussion:

Further to the PDCO discussions held in June 2015, a group of PDCO experts reflected on the need to reconsider the current position of the PDCO to always grant full waivers for this type of medicines. An initial draft position on the development of Fixed Dose Combinations of antihypertensive drugs was presented to the Committee. The PDCO welcomed the work of the group and agreed that discussions should be continued at future plenary meeting when proposals for next steps would be elaborated.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The meeting was cancelled due to time constraints.

11.1.2. Neonatology

Summary of committee discussion:

Participation in international (e.g. International Neonatal Consortium) and organisational matters of internal activities were discussed.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the DD Month YEAR meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Jacqueline Carleer	Alternate	Belgium	No restrictions applicable to this meeting	
Violeta Iotova	Member	Bulgaria	No participation in discussions, final deliberations and voting	EMEA-001030-PIP01-10-M04 EMEA-000498-PIP01-08-M05 EMEA-000828-PIP01-09-M04 EMEA-000200-PIP01-08-M05 EMEA-000694-PIP01-09-M06 EMEA-C-000479-PIP01-08-M03 EMEA-001441-PIP02-15
Suzana Mimica Matanovic	Member	Croatia	No participation in discussions, final deliberations and voting	EMEA-001310-PIP01-12-M02 EMEA-001638-PIP01-14-M01
Marina Dimov Di Giusti	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Peter Szitanyi	Alternate	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Marta Granström	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Maija Pihlajamaki	Member	Finland	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Birka Lehmann	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Grigorios Melas	Member	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No restrictions applicable to this meeting	
John-Joseph Borg	Member	Malta	No interests declared	
Hendrik van den Berg	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Ine Skottheim Rusten	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Jolanta Witkowska-Ozogowska	Alternate	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández	Alternate	Spain	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Cortizo				
Ninna Gullberg	Member	Sweden	No restrictions applicable to this meeting	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Riccardo Riccardi	Member	Healthcare Professionals' Representative	No participation in discussions, final deliberations and voting	EMEA-000174-PIP01-07
Johannes Taminiau	Member via TC	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No participation in discussions, final deliberations and voting	EMEA-000332-PIP01-08-M09 EMEA-000019-PIP08-12-M01 EMEA-001811-PIP01-15
Günther Auerswald	Member	Patients' Organisation Representative	No participation in discussions, final deliberations and voting	EMEA-001296-PIP01-12-M02 EMEA-001215-PIP01-11-M04
Tsvetana Schyns-Liharska	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Nasir Hussain	Expert – in person*	Expert recommended by EMA	No interests declared	
Elmer Schabel	Expert – via telephone*	Expert recommended by EMA	No interests declared	
A representative from the European Commission attended the meeting *For CMDh:* Ad hoc experts* and a representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the product(s) they have been invited to talk about.

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website:
www.ema.europa.eu/